跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 8,190 条关于
“Ruvidar (TLD-1433)”
全部
8,190
临床试验
2,971
药物
1,279
机构
3,781
资讯
159
去年
Theralase Expands Bladder Cancer Clinical Trial with New Sites and Promising Phase II Data
18天前
Theralase Reports 65.2% Complete Response Rate in Phase II Bladder Cancer Study, Plans NDA Filing in 3Q2026
去年
Theralase's Light-Activated Bladder Cancer Therapy Shows Promising Results in Phase II Trial
去年
Theralase's Light-Activated Ruvidar Shows Promising Results in BCG-Unresponsive Bladder Cancer Clinical Trial
去年
Breakthroughs in Bladder Cancer Treatment Highlighted in 2024
去年
Theralase's Ruvidar Shows Promise as DUB Inhibitor in Cancer Treatment Breakthrough
去年
Theralase's Ruvidar® Shows Complete Healing of HSV-1 Lesions in Preclinical Study
9个月前
Theralase Completes Enrollment of 90 Patients in Phase II Bladder Cancer Study for Light-Activated Ruvidar
上个月
Zimbabwe's Black Market ARV Use in Poultry: A Growing Public Health Threat
去年
HIV Drug Resistance Declining in South Africa, but Integrase Inhibitor Resistance Requires Vigilance
第 1 页,共 16 页
上一页
下一页